Intraocular Bevacizumab (Avastin) for Rubeosis Iridis
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) is an anti-VEGF recombinant humanized
monoclonal IgG1 antibody used to treat colorectal cancers. Bevacizumab may have a role in
treating ocular disorders involving fibrovascular proliferation. To determine whether
intraocular bevacizumab decreases rubeosis iridis in patients with neovascular glaucoma.